<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824419</url>
  </required_header>
  <id_info>
    <org_study_id>T16/2015</org_study_id>
    <nct_id>NCT02824419</nct_id>
  </id_info>
  <brief_title>Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis</brief_title>
  <official_title>Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the current study is to evaluate the potential of the selected PET tracers to
      detect sarcoidotic lesions in lungs. The tracers are already in clinical use for the
      detection of certain inflammatory processes or malignant tumors, and their targets present
      similarities with molecular mechanisms of sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of sarcoidosis is difficult since there is no specific noninvasive method
      available to diagnose sarcoidosis. FDG-PET imaging is in use, however, FDG is not a specific
      tracer for sarcoidosis and other inflammatory diseases may interfere with the imaging
      findings. The aim of the current protocol is to evaluate the potential of other inflammatory
      PET-tracers in the detection of sarcoidotic lesions.

      The patients with active sarcoidotic lesions in lungs will be recruited. First, the patient
      undergoes PET-FDG scan and then the patient undergoes the PET scan either with C11-methionine
      or 68Ga-DOTANOC. The results with the latter tracers will be compared to the imaging results
      with FDG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The detection of sarcoidotic lesion with C11-methionine or 68Ga-DOTANOC.</measure>
    <time_frame>baseline</time_frame>
    <description>Qualitative assessment of tracer uptake in sarcoidotic lesions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>C11-methionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To compare FDG and C11-methionine in the detection of sarcoidotic lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga-Dotanoc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methionine</intervention_name>
    <description>Subject undergoes imaging studies with FDG and with methionine.</description>
    <arm_group_label>C11-methionine</arm_group_label>
    <other_name>PET tracers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOTANOC</intervention_name>
    <description>Subject undergoes imaging studies with FDG and with DOTANOC.</description>
    <arm_group_label>68Ga-Dotanoc</arm_group_label>
    <other_name>PET tracers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with sarcoidosis

        Exclusion Criteria:

          -  any malignant disease

          -  any significant other inflammatory or infectious disease affecting lungs

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juhani Knuuti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre, Turku University Hospital, Turku, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riikka Lautamaki, MD, PhD</last_name>
    <phone>+3582 3130000</phone>
    <email>riikka.lautamaki@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riikka Lautamaki, MD, PhD</last_name>
      <phone>+358 2 313 0000</phone>
      <email>riikka.lautamaki@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Juhani Knuuti, MD, PhD</last_name>
      <phone>+358 2 313 0000</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

